# Ralph A. DeFronzo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ralph-a-defronzo-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,207 |
| Field | Diabetes Treatment and Management |
| h-index | 99 |
| i10-index | 263 |
| Last Known Institution | The University of Texas at San Antonio Health Science Center |
| OpenAlex ID | https://openalex.org/A5091912602 |
| ORCID iD | https://orcid.org/0000-0003-3839-1724 |
| Works | 408 |

## Researcher papers

- [Impaired Fasting Glucose and Impaired Glucose Tolerance](https://scholariq.org/papers/impaired-fasting-glucose-and-impaired-glucose-tolerance/)
- [Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY](https://scholariq.org/papers/consensus-statement-by-the-american-association-of-clinical-endocrinologists-and/)
- [Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.](https://scholariq.org/papers/glucose-and-free-fatty-acid-metabolism-in-non-insulin-dependent-diabetes/)
- [Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance](https://scholariq.org/papers/pioglitazone-for-diabetes-prevention-in-impaired-glucose-tolerance/)
- [Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary](https://scholariq.org/papers/consensus-statement-by-the-american-association-of-clinical-endocrinologists-and-2/)
- [Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin](https://scholariq.org/papers/combination-of-empagliflozin-and-linagliptin-as-second-line-therapy-in-subjects/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

## Researcher university

- [The University of Texas at San Antonio Health Science Center](https://scholariq.org/institutions/the-university-of-texas-at-san-antonio-health-science-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.